These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 9387205)

  • 1. Interferon-alpha therapy in polycythemia vera and essential thrombocythemia.
    Elliott MA; Tefferi A
    Semin Thromb Hemost; 1997; 23(5):463-72. PubMed ID: 9387205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2013 Jun; 88(6):507-16. PubMed ID: 23695894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A
    Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expertise-based management in essential thrombocythemia and polycythemia vera.
    Finazzi G; Barbui T
    Cancer J; 2007; 13(6):372-6. PubMed ID: 18032974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2011 Mar; 86(3):292-301. PubMed ID: 21351120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Successful treatment with interferon-alpha in a case of acute myeloid leukemia with del (20q) following polycythemia vera].
    Sumi M; Tauchi T; Takaku T; Ohyashiki JH; Ohyashiki K
    Rinsho Ketsueki; 2005 Nov; 46(11):1208-12. PubMed ID: 16440805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Use of interferon in the treatment of chronic myeloproliferative disorders].
    Robak T
    Acta Haematol Pol; 1992; 23(2 Suppl 1):30-7. PubMed ID: 1488870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
    Barbui T; Finazzi G
    Semin Thromb Hemost; 2007 Jun; 33(4):321-9. PubMed ID: 17525889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk-adapted therapy in essential thrombocythemia and polycythemia vera.
    Finazzi G; Barbui T
    Blood Rev; 2005 Sep; 19(5):243-52. PubMed ID: 15963833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment?
    Hasselbalch HC
    Leuk Res; 2009 Jan; 33(1):11-8. PubMed ID: 18632152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polycythemia vera and essential thrombocythemia in young patients.
    Frezzato M; Ruggeri M; Castaman G; Rodeghiero F
    Haematologica; 1993; 78(6 Suppl 2):11-7. PubMed ID: 8039752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interferon-alpha in the treatment of myeloproliferative syndromes].
    Ballarino P; Castello G; Lerza R
    Recenti Prog Med; 1994 Nov; 85(11):546-50. PubMed ID: 7855389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group.
    Michiels JJ; Juvonen E
    Semin Thromb Hemost; 1997; 23(4):339-47. PubMed ID: 9263350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha.
    Silver RT
    Cancer; 2006 Aug; 107(3):451-8. PubMed ID: 16804923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD).
    Murphy S
    Thromb Haemost; 1997 Jul; 78(1):622-6. PubMed ID: 9198227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group.
    Radin AI; Kim HT; Grant BW; Bennett JM; Kirkwood JM; Stewart JA; Hahn RG; Dutcher JP; Wiernik PH; Oken MM;
    Cancer; 2003 Jul; 98(1):100-9. PubMed ID: 12833462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.